ID   S462
AC   CVCL_1Y70
SY   Patient 6 cell line
DR   EFO; EFO_0006292
DR   cancercelllines; CVCL_1Y70
DR   Cosmic; 1132062
DR   Cosmic; 1801809
DR   DepMap; ACH-002693
DR   Millipore; SCC414
DR   Wikidata; Q54951928
RX   PubMed=15207265;
RX   PubMed=15735744;
RX   PubMed=18650488;
RX   PubMed=21084276;
RX   PubMed=21695156;
RX   PubMed=23437333;
RX   PubMed=28556483;
RX   PubMed=32642732;
RX   PubMed=34059954;
RX   PubMed=36818284;
RX   PubMed=37798904;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Characteristics: Tumorigenic (PubMed=37798904).
CC   Doubling time: ~16 hours (PubMed=21084276); 1.61 days (PubMed=37798904).
CC   Karyotypic information: Average ploidy of 3.85 (PubMed=36818284).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Heterozygous; Note=By translocation (PubMed=34059954).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Heterozygous (PubMed=34059954).
CC   Sequence variation: Gene deletion; HGNC; HGNC:7765; NF1; Zygosity=Heterozygous (PubMed=15207265; PubMed=36818284).
CC   Sequence variation: Gene deletion; HGNC; HGNC:11998; TP53; Zygosity=Heterozygous (PubMed=15207265).
CC   Sequence variation: Mutation; HGNC; HGNC:7765; NF1; Simple; p.Tyr2285Ter (c.6855C>A) (p.Tyr2264Ter, c.6792C>A); ClinVar=VCV000185082; Zygosity=Heterozygous; Note=Germline (PubMed=15207265; PubMed=36818284; DepMap=ACH-002693).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg110Pro (c.329G>C); ClinVar=VCV000233627; Zygosity=Heterozygous (PubMed=21084276; DepMap=ACH-002693).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Genomics; Whole genome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: In situ; Thigh; UBERON=UBERON_0000376.
ST   Source(s): Millipore=SCC414; PubMed=28556483; PubMed=36818284
ST   Amelogenin: X
ST   CSF1PO: 12 (PubMed=36818284)
ST   CSF1PO: 12,13 (Millipore=SCC414; PubMed=28556483)
ST   D13S317: 12
ST   D16S539: 11,13 (PubMed=36818284)
ST   D16S539: 13 (Millipore=SCC414; PubMed=28556483)
ST   D18S51: 16
ST   D19S433: 14
ST   D21S11: 29 (PubMed=36818284)
ST   D21S11: 29,31 (Millipore=SCC414; PubMed=28556483)
ST   D2S1338: 23
ST   D3S1358: 14,17
ST   D5S818: 12 (PubMed=36818284)
ST   D5S818: 12,13 (Millipore=SCC414; PubMed=28556483)
ST   D7S820: 8,10
ST   D8S1179: 10,12
ST   FGA: 20
ST   Penta D: 9,11
ST   Penta E: 11
ST   TH01: 7,8 (PubMed=36818284)
ST   TH01: 8 (Millipore=SCC414; PubMed=28556483)
ST   TPOX: 8
ST   vWA: 19
DI   NCIt; C3798; Malignant peripheral nerve sheath tumor
DI   NCIt; C3273; Neurofibromatosis type 1
DI   ORDO; Orphanet_3148; Malignant peripheral nerve sheath tumor
DI   ORDO; Orphanet_636; Neurofibromatosis type 1
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   19Y
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 10-04-25; Version: 16
//
RX   PubMed=15207265; DOI=10.1016/j.nbd.2004.01.006;
RA   Frahm S., Mautner V.-F., Brems H., Legius E., Debiec-Rychter M.,
RA   Friedrich R.E., Knoefel W.T., Peiper M., Kluwe L.;
RT   "Genetic and phenotypic characterization of tumor cells derived from
RT   malignant peripheral nerve sheath tumors of neurofibromatosis type 1
RT   patients.";
RL   Neurobiol. Dis. 16:85-91(2004).
//
RX   PubMed=15735744; DOI=10.1038/sj.onc.1208425;
RA   Mashour G.A., Drissel S.N., Frahm S., Farassati F., Martuza R.L.,
RA   Mautner V.-F., Kindler-Rohrborn A., Kurtz A.;
RT   "Differential modulation of malignant peripheral nerve sheath tumor
RT   growth by omega-3 and omega-6 fatty acids.";
RL   Oncogene 24:2367-2374(2005).
//
RX   PubMed=18650488; DOI=10.1215/15228517-2008-053; PMCID=PMC2719009;
RA   Holtkamp N., Malzer E., Zietsch J., Okuducu A.F., Mucha J., Mawrin C.,
RA   Mautner V.-F., Schildhaus H.-U., von Deimling A.;
RT   "EGFR and erbB2 in malignant peripheral nerve sheath tumors and
RT   implications for targeted therapy.";
RL   Neuro-oncol. 10:946-957(2008).
//
RX   PubMed=21084276; DOI=10.1158/0008-5472.CAN-10-2799; PMCID=PMC3064267;
RA   Lopez G., Torres K.E., Liu J.J.-H., Hernandez B., Young E.D., Belousov R.,
RA   Bolshakov S.V., Lazar A.J.F., Slopis J.M., McCutcheon I.E., McConkey D.J.,
RA   Lev D.C.;
RT   "Autophagic survival in resistance to histone deacetylase inhibitors:
RT   novel strategies to treat malignant peripheral nerve sheath tumors.";
RL   Cancer Res. 71:185-196(2011).
//
RX   PubMed=21695156; DOI=10.1371/journal.pone.0021099; PMCID=PMC3113907;
RA   Spyra M., Kluwe L., Hagel C., Nguyen R., Panse J., Kurtz A.,
RA   Mautner V.-F., Rabkin S.D., Demestre M.;
RT   "Cancer stem cell-like cells derived from malignant peripheral nerve
RT   sheath tumors.";
RL   PLoS ONE 6:e21099.1-e21099.9(2011).
//
RX   PubMed=23437333; DOI=10.1371/journal.pone.0057152; PMCID=PMC3578816;
RA   Reuss D.E., Mucha J., Hagenlocher C., Ehemann V., Kluwe L.,
RA   Mautner V.-F., von Deimling A.;
RT   "Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL
RT   is augmented by loss of NF1 through modulation of MYC/MAD and is
RT   potentiated by curcumin through induction of ROS.";
RL   PLoS ONE 8:e57152.1-e57152.10(2013).
//
RX   PubMed=28556483; DOI=10.1002/1878-0261.12086; PMCID=PMC5579334;
RA   Kolberg M., Bruun J., Murumagi A., Mpindi J.P., Bergsland C.H.,
RA   Holand M., Eilertsen I.A., Danielsen S.A., Kallioniemi O.-P.,
RA   Lothe R.A.;
RT   "Drug sensitivity and resistance testing identifies PLK1 inhibitors
RT   and gemcitabine as potent drugs for malignant peripheral nerve sheath
RT   tumors.";
RL   Mol. Oncol. 11:1156-1171(2017).
//
RX   PubMed=32642732; DOI=10.1093/noajnl/vdz049; PMCID=PMC7317054;
RA   Pemov A., Li H., Presley W., Wallace M.R., Miller D.T.;
RT   "Genetics of human malignant peripheral nerve sheath tumors.";
RL   Neurooncol. Adv. 2:i50-i61(2020).
//
RX   PubMed=34059954; DOI=10.1007/s00439-021-02296-x;
RA   Magallon-Lorenz M., Fernandez-Rodriguez J., Terribas E.,
RA   Creus-Bachiller E., Romagosa C., Estival A., Perez Sidelnikova D.,
RA   Salvador H., Villanueva A., Blanco I., Carrio M., Lazaro C., Serra E.,
RA   Gel B.;
RT   "Chromosomal translocations inactivating CDKN2A support a single path
RT   for malignant peripheral nerve sheath tumor initiation.";
RL   Hum. Genet. 140:1241-1252(2021).
//
RX   PubMed=36818284; DOI=10.1016/j.isci.2023.106096; PMCID=PMC9929861;
RA   Magallon-Lorenz M., Terribas E., Ortega-Bertran S., Creus-Bachiller E.,
RA   Fernandez M., Requena G., Rosas I., Mazuelas H., Uriarte-Arrazola I.,
RA   Negro A., Lausova T., Castellanos E., Blanco I., DeVries G.H.,
RA   Kawashima H., Legius E., Brems H., Mautner V.-F., Kluwe L., Ratner N.,
RA   Wallace M.R., Fernandez-Rodriguez J., Lazaro C., Fletcher J.A.,
RA   Reuss D.E., Carrio M., Gel B., Serra E.;
RT   "Deep genomic analysis of malignant peripheral nerve sheath tumor cell
RT   lines challenges current malignant peripheral nerve sheath tumor
RT   diagnosis.";
RL   iScience 26:106096.1-106096.22(2023).
//
RX   PubMed=37798904; DOI=10.1002/1878-0261.13534; PMCID=PMC10994238;
RA   Creus-Bachiller E., Fernandez-Rodriguez J., Magallon-Lorenz M.,
RA   Ortega-Bertran S., Navas-Rutete S., Romagosa C., Silva T.M.,
RA   Pane Foix M., Estival A., Perez Sidelnikova D., Morell Ginesta M.,
RA   Mazuelas H., Carrio M., Lausova T., Reuss D.E., Gel B., Villanueva A.,
RA   Serra E., Lazaro C.;
RT   "Expanding a precision medicine platform for malignant peripheral
RT   nerve sheath tumors: new patient-derived orthotopic xenografts, cell
RT   lines and tumor entities.";
RL   Mol. Oncol. 18:895-917(2024).
//